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Dear Reader,
As we approach the end of 2016, and publish our final issue of Drugs—Real World Outcomes for the year, we wish to
reflect on another successful year for the journal and for others in the Adis Premier journals portfolio, and to thank all who
have contributed to Drugs—Real World Outcomes over the past 12 months.
An important milestone was reached for Drugs—Real World Outcomes in that the journal content is now available on
PubMed Central. Another of our open access journals, Drug Safety—Case Reports, is also now available on PubMed
Central.
As of September 2016, Drugs—Real World Outcomes’ top 10 downloaded articles from SpringerLink this year were:
Elliott, R.A., Lee, C.Y., Beanland, C. et al. Medicines Management, Medication Errors and Adverse Medication Events
in Older People Referred to a Community Nursing Service: A Retrospective Observational Study. Drugs—Real World
Outcomes (2016) 3: 13.
Kocis, P.T., Liu, G., Makenbaeva, D. et al. Use of Chronic Medications Among Patients with Non-Valvular Atrial
Fibrillation. Drugs—Real World Outcomes (2016) 3: 165.
Mast, G., Fernandes, K., Tadrous, M. et al. Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A
Retrospective, Population-Based Cohort Study. Drugs—Real World Outcomes (2016) 3: 175.
Lajara, R., Nikkel, C. & Abbott, S. The Clinical and Economic Impact of the V-Go Disposable Insulin Delivery Device
for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk. Drugs—Real World Outcomes (2016) 3:
191.
Watras, M.M., Patel, J.P. & Arya, R. Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants?
A Review of the Literature. Drugs—Real World Outcomes (2016) 3: 1.
Mold, J.W. & Holtzclaw, B.J. Selective Serotonin Reuptake Inhibitors and Night Sweats in a Primary Care Population.
Drugs—Real World Outcomes (2015) 2: 29.
Aggarwal, N. Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors.
Drugs—Real World Outcomes (2016) 3: 145.
Rojas-Fernandez, C.H. Can 5-HT3 Antagonists Really Contribute to Serotonin Toxicity? A Call for Clarity and
Pharmacological Law and Order. Drugs—Real World Outcomes (2014) 1: 3.
Muduma, G., Odeyemi, I. & Pollock, R.F. Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative
to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice. Drugs—
Real World Outcomes (2016) 3: 61.
de Jong, J., Garne, E., de Jong-van den Berg, L.T.W. et al. The Risk of Specific Congenital Anomalies in Relation to
Newer Antiepileptic Drugs: A Literature Review. Drugs—Real World Outcomes (2016) 3: 131.
We offer our sincere thanks to all authors who have contributed articles to Drugs—Real World Outcomes over the
course of 2016. Their skill and dedication are critical to the continued publication of the journal. The quality of published
articles is, similarly, testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal’s
content is held to the highest possible standard. We would like to thank the following individuals who acted as reviewers
for Drugs—Real World Outcomes in the last 12 months:
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Donald G. Klepser, USA
Paul T. Kocis, USA
Sam Kosari, Australia
Richard Laing, USA
Cecilie Johannessen Landmark, Norway
Marianne Lisby, Denmark
Eleanor Lucas, USA
Hendrika Luijendijk, The Netherlands
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Louise Mallet, Canada
G. B. John Mancini, Canada
Gloria Manso, Spain
John F. McCarthy, USA
Natalie McCormick, Canada






















Roger E. Thomas, Canada
Philippe Thuillier, France
Petra A. Thurmann, Germany
James E. Tisdale, USA
Giuliano Tocci, Italy
Antonella Tosti, USA
Robert Vander Stichele, Belgium
Bastiaan Venhuis, The Netherlands
Pa-Chun Wang, Taiwan
Juanita Westbury, Australia
Peter K.K. Wong, Australia
Antoinette A. Wozniak, USA
In addition, we would like to thank the members of the journal’s Honorary Editorial Board, who have acted as peer
reviewers and authors, and have provided guidance on journal content, policy and processes:
G.C. Alexander, Johns Hopkins University, Baltimore, MD, USA
A. Beresniak, Data Mining International, Geneva, Switzerland
M.L. Berger, Pfizer, Inc., New York, NY, USA
H. Birnbaum, Analysis Group, Inc., Boston, MA, USA
J.M. Bottomley, Amygdala Ltd., Letchworth Garden City, England
P. Denig, University of Groningen, Groningen, The Netherlands
J.E. Fincham, Presbyterian College School of Pharmacy, Clinton, SC, USA
B. Godman, Karolinska Institutet, Stockholm, Sweden
D. Goldsmith, Goldsmith Pharmacovigilance and Systems, New York, NY, USA
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S. Karve, AstraZeneca, Gaithersburg, MD, USA
N.Y. Kirson, Analysis Group, Inc., Boston, MA, USA
C. Kozma, CK Consulting Associates, St. Helena Island, SC, USA
T. Lasky, MIE Resources, Baltimore, MD, USA
A.A. Mangoni, Flinders University, Adelaide, SA, Australia
S. Mimica-Matanovic, University Hospital Osijek, Osijek, Croatia
A. Modi, Merck, Whitehouse Station, NJ, USA
J.K. Sluggett, Monash University, Parkville, VIC, Australia
K.A. Swanson, University of Oklahoma, Oklahoma City, OK, USA
J.E Ware Jr., University of Massachusetts, Worcester, MA, USA
Q. Zou, The Lewin Group, Falls Church, VA, USA
In other portfolio news, mid-2016 saw the release of the ISI Journal Citation Reports and the latest journal impact
factors. The majority of our journals saw a rise in impact factor against the previous year. Most notably, five of our journals
saw an increase of over 10% in impact factor – The Patient (17.08%), Clinical Drug Investigation (15.99%), the American
Journal of Clinical Dermatology (13.17%), Drug Safety (13.5%), and Drugs (12.43%).
The Adis journals portfolio will expand in 2017, with the launch of PharmacoEconomics—Open. This new journal will
be fully open access and will focus on the publication of applied research on the economic implications and health
outcomes associated with drugs, devices and other healthcare interventions. It joins our other well respected health
outcomes publications, PharmacoEconomics, Applied Health Economics and Health Policy, and The Patient: Patient-
Centered Outcomes Research.
We hope that you have found the articles published throughout 2016 to be both interesting and informative. We have
appreciated the high quality of content contributed to the journal this year and look forward to keeping you up to date with
topical real-world outcomes in 2017.
With best wishes from Dene Peters (Editor-in-Chief) and Kathy Fraser (Deputy Editor).
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.
org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
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